RA
NBIX icon

Rational Advisors’s Neurocrine Biosciences NBIX Stock Holding History

Rational Advisors’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-120
Closed -$12K – 473
2020
Q3 		$12K Buy
+120
New +$13.9K 0.01% 266

Other funds holding NBIX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Rational Advisors's NBIX Position: Q4 2020 in Review

Rational Advisors sold out of Neurocrine Biosciences (NBIX) in Q4 2020, closing a stake of 120 shares — an estimated $12K sold.

Rational Advisors first reported a position in NBIX in Q3 2020 and held it in 1 quarter. The position peaked at $12K in Q3 2020. 405 funds tracked by Wall St. Rank hold NBIX as of Q4 2020.

  • Rational Advisors reported no remaining Neurocrine Biosciences position as of Q4 2020 after selling out during the quarter.
  • Rational Advisors sold 120 Neurocrine Biosciences shares in Q4 2020, an estimated $12K.
  • Rational Advisors first reported a position in Neurocrine Biosciences in Q3 2020 and held it in 1 quarter.
  • Rational Advisors's Neurocrine Biosciences position peaked at $12K in Q3 2020.
  • 405 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q4 2020.

Based on Rational Advisors's 13F filing for Q4 2020, filed 5 Feb 2021.